Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 127 (4), 1312-26

Cysteinyl Leukotrienes in Allergic Inflammation: Strategic Target for Therapy

Affiliations
Review

Cysteinyl Leukotrienes in Allergic Inflammation: Strategic Target for Therapy

William Busse et al. Chest.

Abstract

Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.

Similar articles

See all similar articles

Cited by 30 PubMed Central articles

See all "Cited by" articles

MeSH terms

Feedback